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Abstract
Background: Yttrium-90 radioembolization (90Y-RE) as a treatment for liver tumours induces radiation damage and
hypoxia in liver tissue, which is also a trigger for systemic release of angiogenic factors, potentially stimulating
tumour growth. We examined changes in circulating angiogenic factors following 90Y-RE and investigated the
association between response and angiogenic factors. In this prospective study, 42 patients with unresectable,
chemorefractory metastatic colorectal cancer (CRCLM) were treated with 90Y-RE. Blood samples were collected
pre-treatment and at 0, 1, 3, 7 and 30 days of follow-up. Response was measured with MRI according to RECIST 1.1 at
1 month and subsequently 3-month interval until progressive disease (PD) occurred. Associations between circulating
angiogenic factors and response were examined with linear mixed model analysis.
Results: Following 90Y-RE, three angiogenic factors demonstrated an increase in plasma levels, i.e., vascular endothelial
growth factor (VEGF), hepatocyte growth factor (HGF) and angiopoietin-2 (Ang-2). Non-responders (= PD at 1-month
follow-up, n = 10) had a significant increase of Ang-2 and HGF at 3 and 7 days post treatment compared to responders
(= stable disease or better, n = 32), who showed little to no changes in plasma levels (respectively p = 0.01 and p = 0.007).
Median overall survival was 9.2 months (95% confidence interval 6.1–12.4).
Conclusions: Significant increases in plasma levels of Ang-2 and HGF in the first week after treatment were associated
with rapid progressive disease of liver lesions at 1 month after 90Y-RE. Combination of 90Y-RE with anti-angiogenic therapy
may reduce these effects and result in better response.
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Background
Yttrium-90 radioembolization (90Y-RE) is an intra-arterial
treatment option for patients with liver dominant, unre-
sectable and chemorefractory hepatic malignancies.
Microspheres with a diameter of 30–40 μm are embedded
with the radio-isotope yttrium-90 (90Y) and delivered to
the liver via a catheter in the hepatic artery. These micro-
spheres will travel distally with the blood stream and lodge
at the arteriolar level inside the tumours and normal liver
and cause tumour necrosis through radiation and embolic
effects [1–5].
A possible consequence of locoregional treatment with
90Y-RE is the systemic release of angiogenic growth
factors due to the embolic effect of this treatment, which
can induce growth of untreated lesions or extrahepatic
(micro)metastases and potentially affect patient survival.
A systemic release of growth factors after resection of
the primary colon tumour has already been suggested
based on an increased metabolic activity in liver metas-
tases [6, 7]. Furthermore, in patients with hepatocellular
carcinoma (HCC), a rise in circulating levels of vascular
endothelial growth factor (VEGF) has been described
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following trans arterial chemoembolization (TACE) as
well as after trans arterial bland embolization [8, 9].
Also, serum levels of VEGF were significantly different
between responders and non-responders [8, 10].
Although 90Y-RE is a promising palliative treatment
option for patients with colorectal cancer liver metas-
tases (CRCLM), not all patients experience good
response and some patients show rapid progression of
liver lesions or of extrahepatic lesions. However, few
large studies have been conducted in this specific
patient group and by extension little prospectively
collected evidence on predictive factors for outcome
is available [11]. The variable response rates may be
related to an increase in circulating growth factors, or
even to a higher baseline level of these factors prior
to treatment [12–14]. If an upregulation of angiogenic
factors is related to response, then concomitant use
of anti-angiogenic treatment with radioembolization
may improve patient outcome.
We conducted a prospective cohort study in patients
with colorectal cancer liver metastases treated with 90Y-
RE (resin microspheres) and measured several circulating
angiogenic factors at baseline and at several intervals after
treatment. Aims of the study were (1) to examine changes
in serum levels of several angiogenic factors following 90Y-
RE and (2) to investigate the relationship between plasma




Patients with unresectable and chemorefractory colo-
rectal cancer liver metastases were enrolled in this
prospective cohort study, the RADAR study (RADio-
embolization: Angiogenic factors and Response). This
study was approved of by the institutional review
board (medical ethical committee NL34970.041.11
protocol number 11-172/E). All patients gave written
informed consent to participate in the study and for
the study results to be published.
Treatment and follow-up
An overview of all pre-treatment and follow-up proce-
dures is given in Fig. 1. All patients referred to our centre
for 90Y-RE were screened for eligibility with full medical
history, standard laboratory evaluation (including but
not limited to liver function tests) and 18F-FDG-PET/
CT imaging (including diagnostic multiphasic contrast
enhanced abdominal and thoracic CT). Consensus on
treatment was reached by a tumour board consisting
of physicians from the department of medical oncol-
ogy, department of interventional radiology and de-
partment of nuclear medicine. If there was any doubt
about possible resectable liver disease (e.g. single lesion
or multiple lesions but limited to one liver lobe), a liver
surgeon was consulted additionally.
Yttrium-90 radioembolization was performed by ex-
perienced interventional radiologists in concordance
with international guidelines [15–18]. Vascular anat-
omy was mapped during pre-treatment angiography.
Subsequently, technetium-99 m macro aggregated
albumin (99mTc-MAA) particles were infused and the
intrahepatic and possible extrahepatic distribution of
those was evaluated with SPECT/CT imaging. In a sec-
ond angiographic procedure the yttrium-90 micro-
spheres (SIR-Spheres, SIRTeX Medical Limited,
Sydney, Australia) were infused with the catheter in a
similar position as during pre-treatment angiography.
The injected activity was calculated using the body
surface area (BSA) method in all patients. Distribution
of yttrium-90 microspheres after treatment was evalu-
ated with 90Y-PET imaging.
Baseline blood sample measurements were performed
prior to treatment. Follow-up blood sampling for angio-
genic factors was performed at days 0 (immediately after
injection of the microspheres), 1, 3, 7 and 30 after 90Y-
RE treatment. Blood samples consisted of EDTA and
citrate samples. Platelet free plasma was obtained from
the EDTA sample prior to rapid storage at −80 °C
(within 1 h from sample collection).
Treatment response of liver lesions was evaluated with
RECIST 1.1 on magnetic resonance imaging of the liver,
Fig. 1 Outline of clinical evaluations and study procedures of the RADAR study. 90Y-RE yttrium-90 radioembolization, FU follow-up, PD
progressive disease
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including post-gadolinium series and diffusion-weighted
imaging. MRI was scored by an independent radiologist
specialized in abdominal imaging. In addition, whole
body FDG-PET/CT was performed and read by an
independent experienced nuclear medicine physician.
Tumour response was evaluated for target lesions only,
as well as for all liver lesions and for the whole body.
Analyses of angiogenic factors
The following angiogenic factors were analysed: vascu-
lar endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), angiopoietin-2, basic fibroblast
growth factor (FGF-b), platelet-derived growth factor
(PDGF-BB), stromal cell-derived factor 1 (SDF-1a) and
thrombospondin-1. Measurements were performed
using an in-house developed and validated multiplex
immunoassay based on Luminex technology (xMAP,
Luminex Austin TX USA). Samples were incubated
with antibody-conjugated MagPlex microspheres (Bio-
Rad) for 1 h at room temperature with continuous
shaking, followed by 1-h incubation with biotinylated
antibodies, and 10-min incubation with phycoerythrin-
conjugated streptavidin diluted in high-performance
ELISA buffer (HPE, Sanquin, the Netherlands [19, 20]).
Acquisition was performed with the Bio-Rad FlexMAP3D
(Bio-Rad laboratories, Hercules USA) in combination with
xPONENT software version 4.2 (Luminex). Data was
analysed by 5-parametric curve fitting using Bio-Plex
Manager software, version 6.1.1 (Bio-Rad). Controls were
analysed to assure intra-temporal consistency of the
results.
Statistical analysis
Descriptive statistics were used to explore baseline char-
acteristics and data on response and angiogenic factors.
When boxplots suggested a possible difference between
strata, independent samples t tests were used to evaluate
this. Data were evaluated for Gaussian distribution and
transformed when necessary.
Overall survival was computed as the number of days
from 90Y-RE treatment until date of death. Seven
patients were still alive at study closure and survival was
censored for these patients at a common date (April 8,
2015). Progression-free survival of the liver was calcu-
lated as the number of days from 90Y-RE until docu-
mented disease progression on imaging. Kaplan Meier
estimates for survival intervals were calculated using
SPSS. Comparisons of survival distributions between
strata were done using a log rank test.
To estimate the association between the plasma levels of
angiogenic factors, tumour response and days after treat-
ment (longitudinal data or repeated measures), a linear
mixed model was used on the logarithmic transformed
values. Time points of blood sampling were entered into
the model as a factor, liver response to treatment at 1-
month follow-up was entered as a fixed effect (dichotom-
ous as response: complete response (CR), partial response
(PR) or stable disease (SD); no response: progressive
disease (PD)), and random intercepts were used for the
individual patients (independent data). An additional ana-
lysis was performed to analyse the influence of the
received liver dose on the levels of angiogenic factors by
adding this as a factor in the models. Liver dose was calcu-
lated as administrated activity ðMBqÞtreated liver volume ðmlÞ  50. Model performance
was evaluated with the Akaike information criterion (AIC
values). Significant contribution of separate factors was
tested with ANOVA (χ2).
Results
Patients
A total of 49 patients were included in our study. Seven
patients were not suitable for 90Y-RE due to uncorrect-
able extrahepatic deposition of 99mTc-MAA on SPECT/
CT (n = 4), unsuitable hepatic artery configuration (n = 1),
rapid progression of disease (n = 1) and inadequate
haemoglobin level (n = 1). A total of 42 patients were
treated with 90Y-RE and completed study follow-up.
Mean age was 62 years (female n = 13, male n = 29)
(Table 1). Most patients (n = 30/42 i.e. 71 %) had liver only
disease, while 12 patients had one or more tumour locali-
sations outside the liver, mainly local lymphadenopathy
(mainly in the hepatoduodenal ligament). Any measurable
disease according to RECIST 1.1 outside the liver was
termed extrahepatic disease (EHD). In 3 patients, the pri-
mary colorectal tumour had not been surgically resected,
but treated with chemotherapy and/or radiation and was
no longer metabolically active on 18F-FDG-PET imaging.
All patients had received at least one regimen of systemic
treatment. Systemic treatment was stopped upon progres-
sive disease in 25 patients and due to toxicity in 5 patients.
Twelve (out of 42) patients had declined further systemic
treatment after having received at least one regimen. None
of the patients were using systemic anti-tumour treatment
(chemotherapy or monoclonal antibodies) while treated
with 90Y-RE. A limited number of patients had previously
undergone treatment of liver lesions, mainly surgical
resection. At the time of 90Y-RE, tumour load in the liver
was <25 % in 36 patients. 90Y-RE was performed in one
session for right and left liver lobe in 38 patients, in two
session (right and left liver lobe consecutively) in two
patients, and two patients had only the right lobe treated
(n = 1 only tumour in right lobe, n = 1 infusion of micro-
spheres stopped prematurely due to severe pain).
Tumour response
Proportions of responders were calculated for target le-
sions, whole liver and whole body (Table 2). Even though
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target lesions showed disease control in all patients at 1-
month follow-up (either partial response (PR) or stable
disease (SD)), 10/42 (24%) of these patients had progres-
sive disease of the liver. This was due to the appearance
of new lesions in 8 patients and due to unequivocal pro-
gression of non-target lesions in 2 patients, while all tar-
get lesions showed stable disease. A total of 5/42
patients (12%) were lost to imaging follow-up, mainly
due to clinically progressive disease, hampering hospital
visits for study purposes. At 3-month follow-up 17
patients showed disease control of target lesions, but
considering the entire liver disease control was seen in
11 patients. Partial response of the liver at 6 months
after treatment was seen in 3 patients. At the level of
extrahepatic lesions, disease control rates were clearly
lowest, i.e. 61, 21 and 2% at 1, 3, and 6-months of
follow-up, respectively.
Survival
Median overall survival was 9.2 months (95% confi-
dence interval (CI) 6.1–12.4). Median time to liver
progression was 3.0 months (95% CI 2.8–3.3). A sig-
nificant difference in time to liver progression was
observed between patients with (n = 12) versus without
EHD (n = 30) at baseline (1.4 versus 3.5 months; log
rank test p = 0.001) (Table 3).
Circulating angiogenic factors
A total of 214 blood samples were analysed in 42
patients over 6 time points. In two patients, the blood
sample directly after injection of the microspheres
(+0 days) was not collected, due to symptoms of post-
embolization syndrome directly following 90Y-RE treat-
ment. Most missing values occurred at three and seven
Table 1 Baseline characteristics
Characteristic (total number of patients n = 42)




Mean (range) 62 (34–83)


















Primary tumour surgically resected (number of patients)
Yes 39
No 3





Liver metastases (number of patients)
Synchronous 32
Metachronous 10









Table 1 Baseline characteristics (Continued)
Received bevacizumab (number of patients)
Yes 25
No 17




Mean % (range) 15 (1–50)
Injected activity (MBq) 1508 (670–3675)
Liver dose (Gy)d 44.3 (24.1–87.5)
Baseline characteristic of 42 patients
aNumbers add to more than 42 because some patients had extrahepatic
disease at more than one site
bTransarterial chemoembolization n = 1, radiotherapy n = 1, open/close
procedure for intended RFA n = 1
cBrain n = 1, adrenal gland n = 2, peritoneal lesion n = 1
dAssuming homogeneous distribution of administered activity
MBq megabecquerel, Gy gray
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days after treatment (respectively 16 and 12 missing), as
patients were at that moment often not able to visit the
hospital due to complaints of fever and fatigue, as part
of the postembolization syndrome. At 30-day follow-up,
blood samples were not collected in 4 patients, 2 due to
severe illness from probable radiation induced liver
disease (REILD) and 2 were lost to follow-up.
A range of normal values for these factors is not
available. We observed large variation in baseline an-
giogenic factor levels between patients. Baseline levels
of angiopoietin-2 were higher in patients with median
overall survival (OS) <6 months (median 566.65 pg/ml,
IQR 470.23–969.65 pg/ml) compared with those with
median OS >6 months (median 280.81 pg/ml, IQR
219.17–563.69 pg/ml) (p = 0.048). Patients with extra-
hepatic disease at baseline had significantly higher base-
line values of FGF-b than those with liver only disease.
Following 90Y-RE, three of the investigated angiogenic
factors demonstrated an overall increase in plasma
levels, i.e. VEGF, HGF and Ang-2. Figure 2 shows the
plasma values for these three angiogenic factors, strati-
fied for patients with response (CR, PR or SD, n = 32)
and those with progressive disease (n = 10) of the liver at
1-month follow-up. The linear mixed model analysis
showed that time as a factor did not contribute to the
model performance for FGF-b and SDF-1a, therefore
excluding a significant change over time.
For VEGF, a slight overall rise in plasma level was
observed at 7 days post treatment, though more pro-
nounced in patients with progressive disease at 1 month
after 90Y-RE. This time effect did contribute to the
model performance; however, there was no statistically
significant difference between the model with and with-
out response as a fixed effect (p = 0.28). Liver dose did
not contribute to the model performance either.
Plasma levels of HGF demonstrated a rise promptly
after injection of the microspheres (blood drawn from the
still indwelling sheath in the femoral artery). This holds
true for both responders and non-responders. Yet, plasma
levels of non-responders showed another peak, i.e. at 3
and 7 days after treatment, which was significantly differ-
ent from responders (p = 0.007). Angiopoietin-2 levels
were also statistically significantly higher at 3 and 7 days
after treatment for patients with rapidly progressive dis-
ease, i.e. liver progression at 1-month follow-up, com-
pared to those with disease control (p = 0.01). Model
performances for HGF and angiopoietin-2 did not
improve on adding received liver dose as a factor.
In addition, time variation of angiogenic factors for
two patient subgroups were analysed, i.e. (1) patients
with extrahepatic disease versus patients without extra-
hepatic disease (patients with liver only disease) (Fig. 3)
and (2) patients previously treated with bevacizumab
versus those who had not received bevacizumab (Fig. 4).
There were no statistically significant differences be-
tween the models with and without respectively EHD or
use of bevacizumab as a fixed effect.
Furthermore, a statistically significant difference in
median overall survival was demonstrated between early
responders and non-responders, of 341 (224–458) days
versus 160 (122–198) days respectively (p value 0.003)
(Table 3). There was no difference in baseline value of
HGF and Ang-2 between early responders and non-
responders. No statistically significant differences were
seen between the 10 patients with rapidly progressive
disease at 1-month follow-up and the 32 patients with
CR, PR or SD at 1-month follow-up with respect to a
number of characteristics that can be assumed to be
important influences on prognosis and response, i.e.
liver tumour involvement, performance score, presence
of extrahepatic disease and received liver dose
(Table 4). The difference in Ang-2 levels at 3 and 7 days
after treatment between responders and non-
responders is still statistically significant when compar-
ing patients based on response at three months post
treatment.
Table 2 Response after 90Y-RE treatment
Target lesions Whole liver Including extrahepatic lesions
1 montha 3 months 6 months 1 montha 3 months 6 months 1 montha 3 months 6 months
PR 5 6 3 4 6 3 4 5 1
SD 36 11 2 27 5 1 21 4 0
PD 0 5 1 10 11 2 16 13 5
Deceased 0 4 12 0 4 12 0 4 12
Lost to follow-up 0 2 5 0 2 5 0 2 5
No follow-up due to
earlier PD
- 14 19 - 14 19 - 14 19
Disease control rate
(PR + SD)
41/41 (100%) 17/42 (40%) 5/42 (12%) 31/41 (76%) 11/42 (26%) 4/42 (10%) 25/41 (61%) 9/42 (21%) 1/42 (2%)
aOne-month follow-up was not performed in 1 patient, while this patient was imaged at 3 months after treatment
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Discussion
Yttrium-90 radioembolization is an increasingly utilized
treatment in clinical practice for unresectable and che-
morefractory liver tumours. A large group of patients
who can potentially benefit from this therapy are those
with liver metastases from colorectal cancer [1–3, 5, 11].
Although the group of patients with CRCLM seems rela-
tively homogeneous, response to treatment varies con-
siderably. Probably, more heterogeneity between patients
exists on a cellular level rather than on a macroscopic
level, resulting in a difference in treatment response. At
present, however, no definite evidence for predictive
factors for treatment response of 90Y-RE has been
identified, although for example presence of extrahepatic
disease and performance status have been associated
with survival [21, 22]. In clinical practice, we have
observed that patients with EHD appear to have poorer
response rates to 90Y-RE than those with liver only
disease. Possibly, a systemic trigger of the angiogenic
cascade underlies this phenomenon. With this hypoth-
esis, we started a prospective study to investigate the
angiogenic cascade following treatment with 90Y-RE.
The median overall survival in our group was
9.2 months. This is in accordance with recently published
data on similar patient groups with heavily pre-treated ad-
vanced colorectal cancer, reporting median overall survival
Table 3 Time to progression of liver lesions and overall survival
Number of patients Median overall survival (days (95 % CI)) Median PFS liver (days (95 % CI)) p value (OS and PFS)
EHD at baseline
Yes 12 200 (164–236) 83 (0–179) 0.081
No 30 302 (216–388) 108 (79–137)* 0.007
Metastases
Synchronous 32 255 (151–359) 92 (82–102) 0.266
Metachronous 10 286 (60–512) 92 (88–96) 0.811
Bevacizumab treatment
Yes 25 322 (247–397) 108 (75–141) 0.049
No 17 215 (180–250)* 92 (87–97) 0.614
kRAS status
Wild type 17 302 (244–360) 108 (51–165) 0.074
Mutation 9 166 (75–257) 87 (0–187) 0.05a
Unknown 16 282 (93–470) 92 (91–93)
Previous liver treatment
Yes 12 286 (142–430) 86 (59–113) 0.840
No 30 255 (148–362) 92 (91–94) 0.674
Baseline serum level
Alkaline phosphatase
Elevated 34 249 (159–339) 274 (134–335) 0.048
Normal 8 355 (345–365)* 92 (90–94)* 0.021
Albumin
Decreased 11 166 (94–238) 90 (72–108) 0.003
Normal 31 351 (263–439)* 92 (91–93) 0.078
Treatment setting
Salvage setting 25 215 (137–293) 92 (86–98) 0.030
Non-salvage setting 17 358 (347–369)* 120 (43–197) 0.070
Liver response at 1 month
CR, PR or SD 31 341 (224–458) – 0.003
PD 10b 160 (122–198)* – –
Non-salvage setting: patient declines (further) systemic treatment or systemic treatment must be stopped due to toxicity
*Significant difference, log rank test p < 0.05
PFS progression free survival, EHD extrahepatic disease, PR partial response, SD stable disease, PD progressive disease
aOne patient was not evaluated at 1-month follow-up but first at 3-month follow-up
bp values only comparing wild-type and mutation groups, not for comparison with unknown kRAS status
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ranging from 8.3 to 11.9 months [21, 23–25]. Additionally,
we focused first on the baseline levels of several classic
angiogenic factors. Relatively large variations were found
in baseline plasma levels of these angiogenic factors be-
tween patients. However, there was no apparent threshold
that separated patients with early response from those
with rapid progressive disease (at 1-month follow-up).
Secondly, we evaluated the changes in plasma levels of
angiogenic factors after treatment in relation to treatment
response at 1-month follow-up (Fig. 2). Statistically signifi-
cant differences were found between patients with early
disease control (CR, PR or SD) and those with rapidly pro-
gression (PD) at 1-month follow-up. Both HGF and
angiopoietin-2 plasma levels showed a rise at three and
seven days after treatment in non-responders, while
hardly any changes were seen in responders. In principal,
one would argue that the embolic effect of 90Y-RE, if any,
would be the same in all patients, yet not all of our
Fig. 2 VEGF (top), HGF (middle) and angiopoietin-2 (bottom) levels per time point (baseline, +0, +1, +3, +7 and +30 days post treatment, respectively),
for patients with and without response at 1 month post treatment, i.e. partial response and stable disease (n = 32) versus progressive disease (n = 10)
of the liver
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patients seem to have been equally susceptible to an up-
regulation of angiogenic factors. And at the same time,
this upregulation of angiogenic factors is connected to
early progressive disease and thus perhaps an early pre-
dictor of unfavourable response to treatment.
Furthermore, a statistically significant difference in
median overall survival was observed between re-
sponders and non-responders at 1-month follow-up, 341
(224 – 458) versus 160 (122 – 198) days respectively. No
statistically significant differences in baseline patient
characteristics were observed between these responders
and non-responders. Our findings suggest that 90Y-RE
can cause an increase in circulating angiogenic factors,
which may be predictive of rapid progressive disease.
Over the past decades, several studies have been con-
ducted on systemic release of angiogenic factors after
transarterial treatment of liver tumours. An overview of
these papers is presented in Table 5. The first studies in-
cluded patients with HCC treated with either chemoem-
bolization (TACE) or bland embolization (TAE) and the
focus of angiogenic analysis was on VEGF [8–10, 26].
Suzuki et al. measured serum levels of HGF and VEGF
Fig. 3 VEGF (top), HGF (middle) and angiopoietin-2 (bottom) levels per time point (baseline, +0, +1, +3, +7 and +30 days post treatment, respectively),
for patients with liver only disease and (n = 30) versus patients with extrahepatic disease (n = 12)
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at 1, 3 and 7 days after bland embolization of HCC.
They observed a rise in VEGF at day 7 but did not dem-
onstrate a subsequent fall in VEGF nor did they evaluate
tumour response [9]. Korse et al. included 12 patients
with neuroendocrine tumours into their study and
followed VEGF and endothelin levels during the first
8 days after bland embolization [27]. Unfortunately, they
too did not include tumour response into their study.
Sergio et al. analysed VEGF and b-FGF and the associ-
ation with response at one month after TACE. Response
was not scored according to (modified) RECIST, but
expressed as the percentage of residual activity at CT
imaging, and responders were defined as those with an
ablation rate between 70–100 % and non-responders as
those with residual activity higher than 30 %. Even
though all 71 patients demonstrated an increase in
VEGF level at 30-day follow-up, non-responders showed
the highest increase [10].
Recently, Carpizo et al. [28] have conducted a pilot
study on angiogenic factors and 90Y-RE. They included
Fig. 4 VEGF (top), HGF (middle) and angiopoietin-2 (bottom) levels per time point (baseline, +0, +1, +3, +7 and +30 days post treatment, respectively),
for patients who had previously received bevacizumab (n = 25) and those who did not (n = 17)
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15 patients with CRCLM and 7 patients with HCC and
measured several angiogenic factors, including non-
classical factors such as interleukin-8, at baseline and
during follow-up until 120 days after treatment. As in
our present study, they too demonstrated rises in VEGF
and Ang-2 after treatment, even though their sample
size was rather limited. Unfortunately, they did not
report tumour response in relation to the levels of an-
giogenic factors, but only survival data. Median overall
survival for the entire patient group was 8 months, but
no separate values for CRCLM and HCC patients were
reported.
Meanwhile, the early progression of liver lesions in 10
patients largely consists of the appearance of new liver
lesions (n = 8/10), and not of the growth of (non)target
lesions. Target lesions, in fact, were stable in all 10/10
patients. This supports our hypothesis that an increase
in circulating angiogenic factors may induce growth of
previously invisible hepatic micro-metastases. Even
though these new appearing lesions are located in the
treated organ, the largest arterial flow at the time of
treatment will have been to the macroscopic metastases,
leaving the micro metastases (and of course the normal
liver parenchyma) relatively untreated and susceptible to
growth stimulating factors. Perhaps, the concomitant
use of an anti-angiogenic agent could counteract this
phenomenon. Gorski et al. have described the relation-
ship between VEGF and the anti-tumour effects of ioniz-
ing radiation [29]. They report that VEGF expression is
induced in Lewis lung carcinomas both in vitro and in
vivo after exposure to ionizing radiation. Furthermore,
they demonstrated that treatment of tumour-bearing
mice with a neutralizing antibody to VEGF prior to
Table 5 Overview of previous studies on angiogenic factors and transarterial treatment of liver tumours
Author Year Patients Treatment Factors Samples collected Results




Baseline * Transient increases in many angiogenic cytokines
* Some changes associated with worse OS
n = 7 HCC 6 h, and 3, 14, 30,
60, 90 and 120 days
of follow-up
Korse et al. [27] 2011 n = 12 NET HAE VEGF, ET-1, proET-1 Baseline * VEGF and proET-1 showed temporarily increase
after treatment
1, 2, 3, 4, 5, 6, 7 and
8 days of follow-up
Sergio et al. [10] 2008 n = 71 HCC TACE VEGF, b-FGF, uPA Baseline * VEGF levels were higher in non-responders at
1-month follow-up
3 and 30 days of
follow-up
* Below-median VEGF levels predicted a longer
survival
Shim et al. [26] 2008 n = 147 HCC TACE VEGF Baseline * High increment in serum VEGF level 1–2 days post
treatment was associated with distant metastasis
and unfavourable outcomes1–2 and 30 days of
follow-up
Li et al. [8] 2004 n = 45 HCC TACE VEGF Baseline * A high pre-treatment VEGF level was associated
with poor response
n = 20 benign
disease
1, 3, 7 and 30 days
of follow-up
n = 17 healthy
controls
* VEGF levels increased significantly on the first day
post treatment
Suzuki et al. [9] 1999 n = 38 HCC TAE VEGF, HGF Baseline * No significant alterations in HGF levels
1, 3 and 7 days of
follow-up
* VEGF levels increased significantly at 7 days post
treatment
CRCLM colorectal cancer liver metastases, HCC hepatocellular carcinoma, 90Y-RE yttrium-90 radioembolization, VEGF vascular endothelial growth factor, Ang-2
angiopoietin-2, b-FGF basic fibroblast growth factor, PDGF-BB platelet-derived growth factor subunit BB, TSP-1 thrombospondin-1, IL-8 interleukin-8, NET neuroendocrine
tumours, HAE hepatic artery embolization, ET-1 endothelin-1, proET-1 proendothelin-1, TACE transarterial chemoembolization, uPA urokinase-type plasminogen activator,
TAE transarterial embolization, HGF hepatocyte growth factor
Table 4 Responders (PR or SD) and non-responders (PD) at
1 month after treatment
PR or SD (n = 32) PD (n = 10)




Extrahepatic disease at baseline (n)
Yes 7 5
No 25 5
Tumour load (% of the liver) 12% 22%
Liver dosea (Gy) 45 43
Several patient characteristics of the patients defined as responders (PR or SD)
and those defined as non-responders (PD). No statistically significant differences
were observed
PR partial response, SD stable disease, PD progressive disease, Gy gray
aLiver dose was calculated as (administrated activity(MBq))/(treated liver
volume(ml)) x 50
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irradiation was associated with a greater than additive
anti-tumour effect. With this, they emphasize the poten-
tial importance of combining radiation therapy with sys-
temic anti-angiogenic treatment to increase anti-tumour
effects.
In addition to the above described increase in HGF at
days 3 and 7 after treatment in non-responders, a large
rise in HGF directly after microsphere injection (ap-
proximately 5 min after end of injection) was observed
for all patients. This may be related to the angiographic
procedure itself, with catheter manipulation in the
hepatic arteries, giving rise to this release of hepatocyte
growth factor. One day after treatment, HGF levels have
returned approximately to baseline. During follow-up,
patients with PR or SD at 1 month after treatment did
not experience any other rises in HGF plasma levels
during the first 30 days, contrary to patients with early
PD. Suzuki et al. also investigated HGF levels but did
not find this large increase, because their first follow-up
sample was collected 1 day after treatment instead of
directly after microsphere injection [9].
Survival analysis showed a remarkable difference in
time to liver progression between patients with and
without extrahepatic disease at baseline. Obviously, 90Y-
RE is a liver-directed treatment and any extrahepatic
lesions will not be treated when no systemic therapy is
added. However, in our cohort, patients with extrahe-
patic lesions had earlier progression of liver lesions than
those with liver only disease at baseline. Perhaps this
reflects a more aggressive tumour type that is less
susceptible to radiation damage as well as more prone to
disseminate throughout the body. This may be an
additional reason to primarily select patients with liver
only disease for 90Y-RE as stand-alone treatment, as they
may benefit more with respect to their liver lesions, on
top of the fact that extrahepatic lesions would be left
untreated. For patients with extrahepatic lesions, a com-
bination of 90Y-RE and systemic treatment is perhaps
more suitable [2, 30]. One of the next steps for this
would be a safety study on the concomitant use of beva-
cizumab with 90Y-RE.
An important limitation of our study was the relatively
small sample size that did not allow development of a
clinical prediction model given the limited number of
predictors that can be included into a model with this
sample size. In the following study a larger patient popu-
lation should be included. Advantages of our study were
its prospective design that ensured standardization of
study procedures and the homogeneity of our study
population, consisting of only patients with unresectable
colorectal cancer liver metastases who had previously
received at least 1 regimen of systemic treatment. Fur-
thermore, we have created a special protocol for blood
collection and processing to ensure that platelet free
plasma was produced and all plasma samples were
stored at −80 °C within 60 min, to avoid breakdown of
the angiogenic proteins, to which mainly VEGF is prone
at room temperature. In addition, our study was the first
and largest cohort study to investigate circulating angio-
genic factors after 90Y-RE for CRCLM in relation to
treatment response according to RECIST.
Conclusions
We showed for the first time that a significant rise in
plasma levels of HGF and Ang-2 at 3 and 7 days post
90Y-RE treatment was associated with progressive liver
disease at 1-month follow-up. Moreover, these early
non-responders have significantly worse overall survival
compared to responders, i.e. 5.2 versus 11.1 months. In
addition, our data showed that the presence of extrahe-
patic disease at baseline is a predictor for early disease
progression of the tumours in the liver.
Our results may open the discussion for more strin-
gent patient selection for 90Y-RE, with respect to for
example extrahepatic disease, and combining 90Y-RE
with systemic anti-angiogenetic treatment for better
treatment response in CRCLM salvage patients.
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